ADVERTISEMENT
Initiation of Asenapine for Treating Schizophrenia Associated With Reduced Levels of Utilization and Cost
A retrospective cohort study observed changes in patterns of utilization and cost of health care services associated with initiation of asenapine for the treatment of schizophrenia in adults. The study included 366 patients who initiated asenapine use between August 1, 2009 and December 31, 2012. The index date was identified as the date of the earliest claim for asenapine during the study period.
Related Content:
Schizophrenia Caregivers Experience Greater Resource Utilization and Costs Compared to Others
Direct Medical Cost for Schizophrenia Varies Significantly Across Countries
The mean age of those included in the study was 40.5 years, and 57.1% of participants were women. Patients were less likely to be hospitalized or to visit the emergency room during postindex. The mean total health care costs decreased by $4776 during postindex, but the mean pharmacy costs increased by $828.
Overall, use of asenapine was associated with reduced levels of health care utilization and cost during the 6-month period after therapy initiation as a result of reduced levels of inpatient care.
